首页> 外文期刊>Health economics, policy, and law. >Determinants of branded prescription medicine prices in OECD countries.
【24h】

Determinants of branded prescription medicine prices in OECD countries.

机译:经合组织国家中品牌处方药价格的决定因素。

获取原文
获取原文并翻译 | 示例
           

摘要

This paper investigates the determinants of the prices of branded prescription medicines across different regulatory settings and health care systems, taking into account their launch date, patent status, market dynamics and the regulatory context in which they diffuse. By using volume-weighted price indices, this paper analyzes price levels for a basket of prescription medicines and their differences in 15 OECD countries, including the United States and key European countries, the impact of distribution margins and generic entry on public prices and to what extent innovation, by means of introducing newer classes of medicines, contributes to price formation across countries. In doing so, the paper seeks to understand the factors that contribute to the existing differences in prices across countries, whether at an ex-factory or a retail level. The evidence shows that retail prices for branded prescription medicines in the United States are higher than those in key European and other OECD countries, but not as high as widely thought. Large differences in prices are mainly observed at an ex-factory level, but these are not the prices that consumers and payers pay. Cross-country differences in retail prices are actually not as high as expected and, when controlling for exchange rates, these differences can be even smaller. Product age has a significant effect on prices in all settings after having controlled for other factors. Price convergence is observed across countries for newer prescription medicines compared with older medicines. There is no evidence that originator brand prices fall after generic entry in the United States, a phenomenon known as the 'generics paradox'. Finally, distribution and taxes are important determinants of retail prices in several of the study countries. To the extent that remuneration of the distribution chain and taxation are directly and proportionately linked to product prices this is likely to persist over time.
机译:本文研究了不同监管环境和医疗保健体系中品牌处方药价格的决定因素,并考虑了它们的发布日期,专利状态,市场动态以及其传播的监管环境。通过使用体积加权价格指数,本文分析了一篮子处方药的价格水平及其在15个经合组织国家(包括美国和主要欧洲国家)中的差异,分配利润和仿制药进入对公共价格的影响以及对价格的影响范围内的创新,通过引入较新的药物类别,为各国之间的价格形成做出了贡献。在此过程中,本文试图了解造成国家间现有价格差异的因素,无论是出厂价还是零售价。证据表明,美国品牌处方药的零售价格高于欧洲主要国家和其他经合组织国家的价格,但没有人们普遍认为的高。价格差异很大,主要是在出厂价水平上观察到的,但不是消费者和付款人支付的价格。跨国零售价格差异实际上没有预期的那么高,而在控制汇率时,这些差异可能会更小。在控制了其他因素之后,产品的使用期限在所有设置下都会对价格产生重大影响。与旧药相比,新处方药的价格在各国之间趋于一致。没有证据表明,在美国仿制药进入市场后,发起者品牌价格下降了,这种现象被称为“仿制药悖论”。最后,分配和税收是一些研究国家零售价格的重要决定因素。在某种程度上,分销链的报酬和税收与产品价格成正比关系,这很可能会随着时间的流逝而持续下去。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号